Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Temsirolimus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    56 result(s) found for: Temsirolimus. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2008-003328-45 Sponsor Protocol Number: Start Date*: 2008-10-03
    Sponsor Name:Sahlgrenska Universitetssjukhuset
    Full Title: Klinisk utvecklingsarbete för utvärdering av molykulärt riktad behandling vid metastaserande njurcancer- PETTO
    Medical condition: Metastaserande njurcancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014844-13 Sponsor Protocol Number: 50-2009 Start Date*: 2010-03-16
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Phase I/II clinical trial with Bendamustine and Temsirolimus in patients with relapsed or refractory mantle cell lymphoma that are not eligible for high dose chemotherapy and stem cell transplantat...
    Medical condition: Treatment ot mantle cell lymphoma patients in first or second relapse or refractory disease. Patients should not be eligible for high dose chemotherapy with autologous or allogenous stem cell trans...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011277-33 Sponsor Protocol Number: PZNSL Start Date*: 2009-07-03
    Sponsor Name:Charité - University Hospital of Berlin
    Full Title: A therapy and pharmacokinetics study of temsirolimus in patients with refractory and recidivated primary CNS lymphoma
    Medical condition: Patients with refractory and recidivated primary CNS lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-007665-22 Sponsor Protocol Number: 34720696 Start Date*: 2008-12-18
    Sponsor Name:Vejle Sygehus
    Full Title: En fase II undersøgelse af Temsirolimus og Irinotecan til behandlingsresistente patienter med metastaserende colorectal cancer og KRAS mutationer
    Medical condition: Behandlingsresistente patienter med metastaserende colorectal cancer og KRAS mutationer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052362 Metastatic colorectal cancer LLT
    9.1 10010036 Colorectal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-007045-12 Sponsor Protocol Number: PV RCC 07-01 Start Date*: 2008-02-21
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: An open label, single institution, phase II study of the mTOR inhibitor temsirolimus in unresectable and/or metastatic renal cell carcinoma (RCC) in patients previously treated with both cytokines ...
    Medical condition: renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-010290-21 Sponsor Protocol Number: UMCNONCO200902 Start Date*: 2009-05-20
    Sponsor Name:University Medical Centre Nijmegen St Radboud
    Full Title: A phase Ib study of combination of temsirolimus (Torisel®) and pegylated liposomal doxorubicin (PLD, Doxil®/ Caelyx®) in advanced or recurrent breast, endometrial and ovarian cancer
    Medical condition: advanced or therapy refractory breast cancer, endometrial cancer, or ovarian cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002087-24 Sponsor Protocol Number: CT/11.02 Start Date*: 2011-07-13
    Sponsor Name:Hellenic Oncology Research Group (HORG)
    Full Title: A phase II study of Temsirolimus in patients with advanced hormone - and chemotherapy - resistant prostate cancer.
    Medical condition: Advanced hormone - and chemotherapy - resistant prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012802-38 Sponsor Protocol Number: UMCNONCO200903 Start Date*: 2009-07-01
    Sponsor Name:University Medical Centre Nijmegen St Radboud
    Full Title: Evaluation of the activity of temsirolimus with FLT-PET in patients with renal cell cancer
    Medical condition: advanced (stage IV or recurrent disease) RCC
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014396-43 Sponsor Protocol Number: HN001 (TEMHEAD) Start Date*: 2010-02-09
    Sponsor Name:Medical School Hannover
    Full Title: A single arm, open-label multicenter phase II trial of temsirolimus in patients with relapsed/ recurrent squamous cell cancer of the Head and Neck (HNSCC)
    Medical condition: Patients with metastatic or local recurrenct squamous carcinoma of the head and neck (HNSCC) who have measurable progressive disease after platinum-based radiochemotherapy or recurrence or metastat...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-008478-30 Sponsor Protocol Number: RWZB-09/1 Start Date*: 2009-05-26
    Sponsor Name:Lukaskrankenhaus GmbH
    Full Title: [Targetspezifische Second-line-Therapie des metastasierten Urothelkarzinoms mit Temsirolimus] Target-specific therapy of metastatic urothelial carcinoma with temsirolimus
    Medical condition: Chemotherapy refractory metastatic urothelia carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004743-68 Sponsor Protocol Number: PUMA-NER-4201 Start Date*: 2014-05-06
    Sponsor Name:Puma Biotechnology, Inc.
    Full Title: A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients with Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations
    Medical condition: Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003679-40 Sponsor Protocol Number: BEV-CCI-779-GBM-02 Start Date*: 2008-09-03
    Sponsor Name:Rigshospitalet
    Full Title: A phase II study of temsirolimus and bevacizumab in recurrent glioblastoma multiforme
    Medical condition: Glioblastoma multiforme and progression after prior VEGF-directed therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000171-18 Sponsor Protocol Number: 3066A2-214-WW Start Date*: 2005-05-12
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
    Full Title: A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Stud...
    Medical condition: Multiple Sclerosis (Relapsing-remitting MS and Secondary progressive MS with relapses)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001491-20 Sponsor Protocol Number: STORM-2011 Start Date*: 2012-10-04
    Sponsor Name:Ruprecht-Karls University Heidelberg, Medical Faculty
    Full Title: A phase II trial to evaluate the safety, feasibility and efficacy of a salvage therapy consisting of the mTOR inhibitor Temsirolimus (Torisel™) added to the standard therapy of Rituximab and DHAP f...
    Medical condition: Diffuse large B-cell lymphoma with documented relapse or progression following at least one but a maximum of two prior treatments, aged older than 18 years
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004943 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000371-42 Sponsor Protocol Number: 3066K1-139-US Start Date*: 2007-09-20
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaeuticals Inc.
    Full Title: A Phase I/II Safety and Exploratory Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects with Relapsed/Refractory Solid Tumors
    Medical condition: Relapsed/refractory neuroblastoma,high-grade glioma, and rhabdomyosarcoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018338 Glioma LLT
    9.1 10029260 Neuroblastoma LLT
    9.1 10039022 Rhabdomyosarcoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-018370-21 Sponsor Protocol Number: C-II-007 Start Date*: 2010-05-27
    Sponsor Name:CESAR Central European Society for Anticancer Drug Research EWIV
    Full Title: Phase I/II study with Temsirolimus versus no add-on in patients with castration resistant prostate cancer (CRPC) receiving first-line Docetaxel chemotherapy CESAR Study in Prostrate Cancer wi...
    Medical condition: castration resistant prostate cancer (CRPC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000601-74 Sponsor Protocol Number: PCI-32765MCL3001 Start Date*: 2014-01-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects with Relapsed or Refractory Mantle Cell L...
    Medical condition: Relapsed or refractory Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) DE (Completed) GB (Completed) IE (Completed) HU (Completed) PT (Completed) CZ (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003870-16 Sponsor Protocol Number: AlloTor Start Date*: 2008-09-22
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: A PILOT STUDY OF SEQUENTIAL, NON-MYELOABLATIVE HLA-IDENTICAL SIBLING DONOR ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWED BY IV TEMSIROLIMUS IN PATIENTS WITH ADVANCED, TKI-REFRACTORY CLEAR-CELL RENA...
    Medical condition: PATIENTS WITH ADVANCED, TKI-REFRACTORY CLEAR-CELL RENAL CELL CANCER
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001430-16 Sponsor Protocol Number: 3066K1-305-WW Start Date*: 2005-04-20
    Sponsor Name:Wyeth Research, Division of Wyeth Pharmaceuticals, Inc. Clinical Research and Development
    Full Title: An Open-label, Randomized, Phase 3 Trial of intravenous Temsirolimus (CCI-779) at two Dose Levels Compared to Investigator's Choice Therapy in relapsed, Refractory Subjects with Mantle Cell lymphom...
    Medical condition: Mantle Cell Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) SE (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-005037-37 Sponsor Protocol Number: 10-005 Start Date*: 2013-10-02
    Sponsor Name:Puma Biotechnology, Inc.
    Full Title: A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients with Metastatic HER2-Amplified or Triple-Negative Breast Cancer
    Medical condition: advanced breast carcinoma in patients with trastuzumab-refractory HER2-amplified disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072737 Advanced breast cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 14:21:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA